Wolff Wiese Magana’s Blueprint Medicines BPMC Stock Holding History

Wolff Wiese Magana’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19	Closed	-$2.44K	–	969
2025 Q2	$2.44K	Hold	19	–	–	﹤0.01%	695
2025 Q1	$1.68K	Hold	19	–	–	﹤0.01%	760
2024 Q4	$1.66K	Hold	19	–	–	﹤0.01%	734
2024 Q3	$1.76K	Buy	+19	New	+$1.89K	﹤0.01%	760

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wolff Wiese Magana's BPMC Position: Q3 2025 in Review

Wolff Wiese Magana sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 19 shares — an estimated $2.44K sold.

Wolff Wiese Magana first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $2.44K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Wolff Wiese Magana reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Wolff Wiese Magana sold 19 Blueprint Medicines shares in Q3 2025, an estimated $2.44K.
Wolff Wiese Magana first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
Wolff Wiese Magana's Blueprint Medicines position peaked at $2.44K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Wolff Wiese Magana's 13F filing for Q3 2025, filed 28 Oct 2025.